Rocket Pharmaceuticals, Inc. (RCKT)
NASDAQ: RCKT · Real-Time Price · USD
3.250
-0.150 (-4.41%)
At close: May 15, 2026, 4:00 PM EDT
3.270
+0.020 (0.62%)
After-hours: May 15, 2026, 7:34 PM EDT
Rocket Pharmaceuticals Stock Forecast
Stock Price Forecast
The 12 analysts that cover Rocket Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $29.54, which forecasts a 808.92% increase in the stock price over the next year. The lowest target is $2.50 and the highest is $263.
Price Target: $29.54 (+808.92%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Rocket Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Hold | 5 | 5 | 5 | 4 | 4 | 4 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 1 | 1 | 1 |
| Total | 14 | 14 | 14 | 14 | 14 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $11 | Strong Buy | Maintains | $11 | +238.46% | May 11, 2026 |
| B of A Securities | B of A Securities | Strong Buy Maintains $8 → $9 | Strong Buy | Maintains | $8 → $9 | +176.92% | Mar 30, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $11 | Strong Buy | Maintains | $11 | +238.46% | Mar 27, 2026 |
| Goldman Sachs | Goldman Sachs | Strong Sell Maintains $2 → $3 | Strong Sell | Maintains | $2 → $3 | -7.69% | Mar 2, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $8 → $10 | Buy | Maintains | $8 → $10 | +207.69% | Feb 27, 2026 |
Financial Forecast
Revenue This Year
14.85M
Revenue Next Year
24.40M
from 14.85M
Increased by 64.28%
EPS This Year
-1.15
from -2.01
EPS Next Year
-1.29
from -1.15
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 150.2M | 136.5M | ||||||
| Avg | 14.9M | 24.4M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 819.2% | ||||||
| Avg | - | 64.3% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.07 | -0.83 | ||||||
| Avg | -1.15 | -1.29 | ||||||
| Low | -1.93 | -1.89 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.